Literature DB >> 32399951

Anti-N-methyl-D-aspartate receptor encephalitis: a prospective study focused on cerebrospinal fluid and clinical symptoms.

Shouyi Wu1, Huiqin Li2, Yajun Lian3, Yuan Chen1, Yake Zheng1, Chengze Wang1, Qiaoman Zhang1, Zhi Huang1, Zhengrong Mao4, Kai Pang5.   

Abstract

BACKGROUND AND
OBJECTIVE: To analyze the relationship between brain MRI, clinical symptoms, and cerebrospinal fluid (CSF) and to provide a reference for early diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis.
MATERIALS AND METHODS: A total of 62 patients with anti-NMDAR encephalitis in Zhengzhou, China (2016-2018) were observed and registered prospectively. First, we analyzed the characteristics of clinical symptoms. Second, according to the disease duration, patients were divided into two groups, and then we analyzed the CSF features. In addition, they were divided into two groups according to the brain MRI, and then the CSF features were analyzed. Finally, the characteristics of cerebrospinal fluid in patients with seizure as the initial symptom were analyzed.
RESULTS: Seizure presents as the initial symptom in 14 patients (22.5%), including 11 males (78.57%). The proportion and concentration of CSF total protein abnormalities in the early stage group were significantly higher than those in the middle and late group (P < 0.05). The total protein concentration in the abnormal brain MRI group was significantly higher than that in the normal MRI group (P < 0.05).
CONCLUSION: Anti-NMDAR encephalitis should be suspected, when male patients complain of seizure as an initial symptom and have simultaneously had headaches or fever prior to onset. The sensitivity of anti-NMDAR antibody is higher in CSF than in serum. Total CSF protein is more prone to elevation in the middle and late stages of anti-NMDAR encephalitis. Brain MRI abnormalities with anti-NMDAR encephalitis are related to the total protein concentration of CSF, which may be related to the disease duration.

Entities:  

Keywords:  Anti N-methyl-D-aspartate receptor encephalitis; Autoantibody; Autoimmune encephalitis; Cerebrospinal fluid

Mesh:

Year:  2020        PMID: 32399951     DOI: 10.1007/s10072-020-04451-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  22 in total

Review 1.  Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases.

Authors:  H Reiber
Journal:  Mult Scler       Date:  1998-06       Impact factor: 6.312

2.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

Review 3.  Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens.

Authors:  Luigi Zuliani; Marco Zoccarato; Matteo Gastaldi; Raffaele Iorio; Amelia Evoli; Tiziana Biagioli; Silvia Casagrande; Elena Bazzigaluppi; Raffaella Fazio; Claudia Giannotta; Eduardo Nobile-Orazio; Francesca Andreetta; Ornella Simoncini; Gianna Costa; Sara Mariotto; Sergio Ferrari; Elisabetta Galloni; Michela Marcon; Diego Franciotta; Bruno Giometto
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

Review 4.  Cerebrospinal fluid analysis and the determination of oligoclonal bands.

Authors:  Matteo Gastaldi; Elisabetta Zardini; Rosaria Leante; Maddalena Ruggieri; Gianna Costa; Eleonora Cocco; Giovanna De Luca; Ivana Cataldo; Tiziana Biagioli; Clara Ballerini; Massimiliano Castellazzi; Enrico Fainardi; Paola Pettini; Mauro Zaffaroni; Debora Giunti; Elisabetta Capello; Gaetano Bernardi; Emilio Ciusani; Claudia Giannotta; Eduardo Nobile-Orazio; Elena Bazzigaluppi; Gabriella Passerini; Roberta Bedin; Patrizia Sola; Rinaldo Brivio; Guido Cavaletti; Arianna Sala; Antonio Bertolotto; Gaetano Desina; Maurizio A Leone; Sara Mariotto; Sergio Ferrari; Andreina Paternoster; Davide Giavarina; Francesco Lolli; Diego Franciotta
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

5.  Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.

Authors:  Mark S Freedman; Edward J Thompson; Florian Deisenhammer; Gavin Giovannoni; Guy Grimsley; Geoffrey Keir; Sten Ohman; Michael K Racke; Mohammad Sharief; Christian J M Sindic; Finn Sellebjerg; Wallace W Tourtellotte
Journal:  Arch Neurol       Date:  2005-06

6.  Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients.

Authors:  Thaís Armangue; Maarten J Titulaer; Ignacio Málaga; Luis Bataller; Iñigo Gabilondo; Francesc Graus; Josep Dalmau
Journal:  J Pediatr       Date:  2012-11-16       Impact factor: 4.406

7.  CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis.

Authors:  Rui Wang; Hong-Zhi Guan; Hai-Tao Ren; Wei Wang; Zhen Hong; Dong Zhou
Journal:  Seizure       Date:  2015-04-22       Impact factor: 3.184

8.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.

Authors:  Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch
Journal:  Lancet Neurol       Date:  2008-10-11       Impact factor: 44.182

Review 9.  Diagnostic value of CSF findings in antibody-associated limbic and anti-NMDAR-encephalitis.

Authors:  Michael P Malter; Christian E Elger; Rainer Surges
Journal:  Seizure       Date:  2013-01-11       Impact factor: 3.184

Review 10.  A clinical approach to diagnosis of autoimmune encephalitis.

Authors:  Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau
Journal:  Lancet Neurol       Date:  2016-02-20       Impact factor: 44.182

View more
  5 in total

1.  Clinical characteristics, treatment and long-term prognosis in patients with anti-NMDAR encephalitis.

Authors:  Pritam Raja; Biswas Shamick; L K Nitish; Vikram Venkappayya Holla; P K Pal; Anita Mahadevan; Priya Treesa Thomas; Bhat Maya; J Saini; H Shantala; M Netravathi
Journal:  Neurol Sci       Date:  2021-03-16       Impact factor: 3.307

2.  Influential factors and predictors of anti-N-methyl-D-aspartate receptor encephalitis associated with severity at admission.

Authors:  Xiao-Xue Huang; Shuang Zhang; Lu-Lu Yan; Yao Tang; Jun Wu
Journal:  Neurol Sci       Date:  2021-01-23       Impact factor: 3.307

Review 3.  Diagnostic Value of Structural and Functional Neuroimaging in Autoimmune Epilepsy.

Authors:  Limei Luo; Nian Wei; Jing Wang; Yuemei Luo; Fei Yang; Zucai Xu
Journal:  Contrast Media Mol Imaging       Date:  2020-12-14       Impact factor: 3.161

4.  Case report: Anti-NMDA receptor encephalitis manifesting as rapid weight loss and abnormal movement disorders with alternating unilateral ptosis and contralateral limb tremor.

Authors:  Yue Han; Sizhu Gong; Yafei Wan; Xiyao Fu; Enling He; Min Liu; Fang Deng
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

5.  High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis.

Authors:  Qing Li; Jinglong Chen; Mengzhuo Yin; Jun Zhao; Fuchang Lu; Zhanhang Wang; Xiaoqi Yu; Shuangyan Wang; Dong Zheng; Honghao Wang
Journal:  Front Immunol       Date:  2021-06-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.